Shots:

• AcelRx signs a merger agreement to acquire Lowell for $32.5M in cash and an additional ~$26.0M in contingent consideration upon the achievement of regulatory and sales-based milestones, $3.5M in AcelRx common stock, ~$6.5M is expected to be issued to Lowell security holders at closing. The transaction is expected to close in Q4’21
• The acquisition will expand AcelRx's portfolio into new therapeutic areas within medically supervised settings
• Lowell's LTX-608 is a nafamostat formulation for direct IV infusion which has been developed for ARDS and DIC. AcelRx has in-licensed two innovative pre-filled syringe products under an agreement with Aguettant for the US FDA filing in 2022

  Ref: PR Newswire | Image: Lowell